查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1869869

血尿治疗市场规模、份额和趋势分析报告：按治疗类型、类型、地区和细分市场预测（2025-2033 年）

Hematuria Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Pharmacotherapy, Procedural / Interventional Therapies, Adjunctive / Supportive Therapies), By Type, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

血尿治疗市场摘要

2024年全球血尿治疗市场规模估计为10.873亿美元，预计2033年将达到14.269亿美元。

预计从 2025 年到 2033 年，该市场将以 3.1% 的复合年增长率成长。泌尿系统护理是推动市场成长的主要因素，而復发性尿道感染、膀胱癌和尿道结石的盛行率不断上升，以及老年人口的不断增长，都为市场成长提供了支撑。

血尿是膀胱癌最常见且最重要的早期临床症状，使其成为一种负担沉重的疾病，需要大量的诊断和治疗资源。此外，全球膀胱癌病例的不断增加预计将推动整体市场成长。在美国，美国癌症协会预测2025年将新增84,870例膀胱癌病例，反映出发生率稳定，且诊断性膀胱镜检查仍是主要依赖手段。由于大多数膀胱癌需要持续后续观察，包括重复膀胱镜检查和风险适应性膀胱内治疗，因此病例数量的增加正在推动血尿治疗行业的发展。

此外，尿道感染（UTI）发生率的上升导致阵发性血尿就诊量增加，经验性抗生素的使用也随之增多，从而推高了对紧急评估的需求，并对快速照护现场诊断提出了更高的要求。新的快速诊断方法缩短了病原体鑑定时间，并透过缩短诊断时间直接影响血尿的治疗路径。

尿道结石及其症状是肉眼血尿的重要非肿瘤性原因，通常需要内视镜泌尿外科治疗（内视镜泌尿外科手术、经皮肾镜取石术）和影像学检查。虽然一些地区的年龄调整发生率有所下降，但绝对病例数和新发病例数在许多地区仍在增加。此疾病的特征是症状明显且復发率高，尤其影响20至54岁的人群，对医疗保健系统带来沉重负担。这显示许多地区结石疾病的年龄调整盛行率显着偏高且呈上升趋势，导致急诊和择期手术数量增加。由于结石和血尿就诊人数不断增加，诊断性膀胱镜检查仍然是泌尿系统最常进行的检查之一。

目录

第一章调查方法和范围

第二章执行摘要

第三章 血尿治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 血尿治疗市场分析工具
    • 产业分析—波特五力分析
    • PESTEL 分析

第四章 血尿治疗市场：治疗类型估算与趋势分析

  • 治疗类型细分仪表板
  • 血尿治疗市场：治疗类型差异分析
  • 全球血尿治疗市场规模及趋势分析（依治疗类型划分，2021-2033 年）
    • 药物治疗
    • 治疗/干预
    • 辅助性治疗/支持性护理

第五章 血尿治疗市场：类型估算与趋势分析

  • 类型细分仪表板
  • 血尿治疗市场：类型差异分析
  • 全球血尿治疗市场规模及趋势分析（按类型划分）（2021-2033 年）
    • 品牌
    • 非专利的

第六章 血尿治疗市场：区域估算与趋势分析

  • 区域市场概览
  • 2024 年及 2030 年区域市占率分析
  • 按地区分類的血尿治疗市场：重点
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争情势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商概况
  • 公司简介
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson &Johnson and its affiliates
    • Merck &Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd.
Product Code: GVR-4-68040-783-3

Hematuria Treatment Market Summary

The global hematuria treatment market size was estimated at USD 1,087.3 million in 2024 and is projected to reach USD 1,426.9 million by 2033, growing at a CAGR of 3.1% from 2025 to 2033. The market is driven by urological care and sustained by the growing prevalence of recurrent urinary tract infections, bladder cancer, and urolithiasis, alongside an expanding geriatric population.

Hematuria is the most common and vital early clinical sign for bladder cancer, which is a high-burden disease that requires extensive diagnostic and therapeutic resources. Moreover, the increasing incidence of bladder cancer cases globally is expected to drive the overall market growth. In the U.S., the American Cancer Society projects 84,870 new cases in 2025, reflecting stable incidence and continued reliance on diagnostic cystoscopy. Given that most bladder cancers require ongoing surveillance through repeated cystoscopy and risk-adapted intravesical therapy, rising case volumes drive the hematuria treatment industry.

Furthermore, rising urinary tract infection (UTI) incidence increases episodic hematuria presentations and empirical antibiotic use, which drives urgent evaluation demand and creates pressure for faster, point-of-care diagnostics. New rapid diagnostics have shortened pathogen identification, directly affecting hematuria treatment pathways by shortening time-to-diagnosis.

Urolithiasis prevalence and symptomatic stone events are important non-neoplastic causes of visible hematuria and often require definitive endourologic care (URS, PCNL) or imaging triage. Although some age-standardised rates have declined, absolute case counts, and new presentations have risen in many regions. It is characterized by symptoms and a high likelihood of recurrence and has created a considerable burden on the healthcare system, especially affecting individuals aged 20 to 54. This indicates substantial age-standardized incidence of stone disease and rising rates in many regions, which raises emergency and elective procedure volumes. Diagnostic cystoscopy remains among the most frequently performed urology procedures, so rising stone and hematuria referrals drive the industry.

Global Hematuria Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hematuria treatment market report based on treatment type, type, and region:

  • Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmacotherapy
  • Procedural / Interventional Therapies
  • Adjunctive / Supportive Therapies
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Branded
  • Generic
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment type
    • 1.2.2. Type
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment type outlook
    • 2.2.2. Type outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hematuria Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Hematuria Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Hematuria Treatment Market: Treatment Type Estimates & Trend Analysis

  • 4.1. Treatment Type Segment Dashboard
  • 4.2. Hematuria Treatment Market: Treatment Type Movement Analysis
  • 4.3. Global Hematuria Treatment Market Size & Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
    • 4.3.1. Pharmacotherapy
      • 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.2. Procedural / Interventional Therapies
      • 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.3. Adjunctive / Supportive Therapies
      • 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Hematuria Treatment Market: Type Estimates & Trend Analysis

  • 5.1. Type Segment Dashboard
  • 5.2. Hematuria Treatment Market: Type Movement Analysis
  • 5.3. Global Hematuria Treatment Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
    • 5.3.1. Branded
      • 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.2. Generic
      • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Hematuria Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Hematuria Treatment Market by Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Germany
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.3. France
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.4. Italy
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.6. Denmark
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework/reimbursement structure
      • 6.5.7.3. Competitive scenario
      • 6.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key country dynamics
      • 6.5.8.2. Regulatory framework/reimbursement structure
      • 6.5.8.3. Competitive scenario
      • 6.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.4. South Korea
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.6. Thailand
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.2. Mexico
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.3. UAE
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key country dynamics
      • 6.8.4.2. Regulatory framework/reimbursement structure
      • 6.8.4.3. Competitive scenario
      • 6.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company heat map analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. AstraZeneca
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Bristol-Myers Squibb Company
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. F. Hoffmann-La Roche Ltd.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Johnson & Johnson and its affiliates
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Merck & Co., Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Novartis AG
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Pfizer Inc.
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Sun Pharmaceutical Industries Ltd.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiativesa

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global hematuria treatment market, by region, 2021 - 2033 (USD Million)
  • Table 3 Global hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 4 Global hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 5 North America hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 6 North America hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 7 North America hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 8 U.S. hematuria treatment, by treatment type, 2021 - 2033 (USD Million)
  • Table 9 U.S. hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 10 Canada hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 11 Canada hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 12 Europe hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 13 Europe hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 14 Europe hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 15 Germany hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 16 Germany hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 17 UK hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 18 UK hematuria treatment market, by drug, 2021 - 2033 (USD Million)
  • Table 19 France hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 20 France hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 21 Italy hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 22 Italy hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 23 Spain hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 24 Spain hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 25 Denmark hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 26 Denmark hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 27 Sweden hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 28 Sweden hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 29 Norway hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 30 Norway hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 31 Asia Pacific hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 32 Asia Pacific hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 33 Asia Pacific hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 34 Japan hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 35 Japan hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 36 China hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 37 China hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 38 India hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 39 India hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 40 South Korea hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 41 South Korea hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 42 Australia hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 43 Australia hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 44 Thailand hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 45 Thailand hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 46 Latin America hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 47 Latin America hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 48 Latin America hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 49 Brazil hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 50 Brazil hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 51 Mexico hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 52 Mexico hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 53 Argentina hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 54 Argentina hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 55 MEA hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 56 MEA hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 57 MEA hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 58 South Africa hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 59 South Africa hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 60 Saudi Arabia hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 62 UAE hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 63 UAE hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 64 Kuwait hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 65 Kuwait hematuria treatment market, by type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Hematuria treatment market: market outlook
  • Fig. 9 Hematuria treatment competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Hematuria treatment market driver impact
  • Fig. 14 Hematuria treatment market restraint impact
  • Fig. 15 Hematuria treatment market strategic initiatives analysis
  • Fig. 16 Hematuria treatment market: treatment type movement analysis
  • Fig. 17 Hematuria treatment market: treatment type outlook and key takeaways
  • Fig. 18 Pharmacotherapy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 Procedural /Interventional therapies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Adjunctive / Supportive therapies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Hematuria treatment market: type movement analysis
  • Fig. 22 Hematuria treatment market: type outlook and key takeaways
  • Fig. 23 Branded market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Generic market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Global hematuria treatment market: Regional movement analysis
  • Fig. 26 Global hematuria treatment market: Regional outlook and key takeaways
  • Fig. 27 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)